Review Article

Published: Nov 08, 2026 | DOI: 10.24911/amem.15-3231

Impact of vericiguat on mortality and hospitalization in HFrEF: a systematic review, meta‑analysis, and meta-regression


Authors: Ihab Suliman , Noor Yousef Al-Mohaimeed , Hisham Ali Hendi Alghamdi , Saja Abdullah Alharbi , Leen Ghazi Alahmadi , Sabah Hussein Alkharboush , Layan Tareq Aldhowayan , Manahel Hayder H. Alawami , Abdulrahman Mohammed H. M. Aldousari , Salah J. S. A. A. Alrashidi , Rahaf Mohammed Alansari


Abstract

Background: Patients with heart failure with reduced ejection fraction (HFrEF) remain at high risk despite guideline‑directed therapy. Vericiguat, an oral soluble guanylate cyclase stimulator, has emerged as a novel option. We conducted a systematic review and meta‑analysis to evaluate its efficacy and safety.

Methods: Randomized, double‑blind, placebo‑controlled trials of vericiguat in adults with chronic HFrEF were identified through November 2025. The primary outcome was cardiovascular (CV) death or heart failure (HF) hospitalization; secondary outcomes included CV death, HF hospitalization, all‑cause mortality, and safety endpoints.

Results: Three trials enrolling >11,000 patients were analyzed. Vericiguat reduced the composite of CV death or HF hospitalization (RR 0.91, 95% CI 0.86–0.97) and lowered HF hospitalization risk, including recurrent events. All‑cause mortality showed modest reduction, while CV mortality alone was not significantly reduced. Safety analyses revealed slightly higher risks of hypotension and anemia, but no excess syncope or kidney injury.

Conclusion: Vericiguat offers modest but clinically relevant benefits in reducing heart failure hospitalizations and composite cardiovascular outcomes in HFrEF. Its safety profile is generally acceptable, with only slight increases in hypotension and anemia. These findings support its role as an adjunctive therapy for selected high‑risk patients.

 

 

 


Keywords: Vericiguat, heart failure with reduced ejection fraction (HFrEF), heart failure hospitalization, cardi‑ ovascular outcomes, meta‑analysis.



Pubmed Style

Ihab Suliman, Noor Yousef Al-Mohaimeed, Hisham Ali Hendi Alghamdi, Saja Abdullah Alharbi, Leen Ghazi Alahmadi, Sabah Hussein Alkharboush, Layan Tareq Aldhowayan, Manahel Hayder H. Alawami, Abdulrahman Mohammed H. M. Aldousari, Salah J. S. A. A. Alrashidi, Rahaf Mohammed Alansari. Impact of vericiguat on mortality and hospitalization in HFrEF: a systematic review, meta‑analysis, and meta-regression. AMEM. 2026; 08 (November 2026): -. doi:10.24911/amem.15-3231

Publication History

Received: October 06, 2026

Revised: October 15, 2026

Accepted: October 21, 2026

Published: November 08, 2026


Authors

Ihab Suliman

Cardiology, King Abdulaziz Medical City, King Abdulaziz Cardiac Center, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.

Noor Yousef Al-Mohaimeed

College of Medicine, Qassim University, Buraydah, Saudi Arabia.

Hisham Ali Hendi Alghamdi

Faculty of Medicine, Al Baha University, Al Baha, Saudi Arabia.

Saja Abdullah Alharbi

College of Medicine, Majmaah University, Majmaah, Saudi Arabia.

Leen Ghazi Alahmadi

College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

Sabah Hussein Alkharboush

Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia.

Layan Tareq Aldhowayan

College of Medicine, Qassim University, Buraydah, Saudi Arabia.

Manahel Hayder H. Alawami

College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.

Abdulrahman Mohammed H. M. Aldousari

Department of Internal Medicine, Farwaniya Hospital, Ministry of Health, Farwaniya, Kuwait.

Salah J. S. A. A. Alrashidi

Department of Internal Medicine, Al Sabah Medical Hospital, Ministry of Health, Kuwait City, Kuwait.

Rahaf Mohammed Alansari

Faculty of Medicine, University of Tabuk, Tabuk, Saudi Arabia.